Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

Neily Zakiyah*, Widya N. Insani, Auliya A. Suwantika, Jurjen van der Schans, Maarten J. Postma

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Downloads (Pure)

Abstract

Background: Evidence on costs and health benefits of pneumococcal conjugate vaccine (PCV) for children in Asian countries is limited but growing. As a region with a considerably high burden of pneumococcal disease, it is prominent to have a comprehensive overview on the cost-effectiveness of implementing and adopting a PCV vaccination program. Methods: We conducted a systematic review from Pubmed and Embase to identify economic evaluation studies of PCV for children in Asian countries up to May 2020. Data extraction included specific characteristics of the study, input parameters, cost elements, cost-effectiveness results, and key drivers of uncertainty. The Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement was followed for this systematic review. The reporting quality of the included studies was evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Results: After the screening process on both the title and abstract and full text of 518 records, a total of 25 studies fulfilled the inclusion criteria, and were included in the review. The majority of included studies demonstrates that PCV for children is cost-effective in most of the Asian region, and even cost-saving in some countries. Most of the included studies implemented cost utility analysis (CUA) using either quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). Overall, the main drivers affecting the cost effectiveness were vaccine price, burden regarding pneumonia-related parameters, and the inclusion of herd effects. Conclusion: The children pneumococcal vaccination program appears to be a cost-effective intervention in Asia, and even cost-saving in certain conditions. Vaccine price, pneumonia-related disease burden, and the inclusion of the herd effect are observed as important key drivers in estimating cost-effectiveness in this region. Incorporating PCV in vaccination programs in this region was found to be highly favorable.

Original languageEnglish
Article number426
Number of pages18
JournalVaccines
Volume8
Issue number3
DOIs
Publication statusPublished - Sep-2020

Keywords

  • Asia
  • cost analysis
  • cost-effectiveness
  • children
  • pneumococcal conjugate vaccine
  • COST-EFFECTIVENESS ANALYSIS
  • D CONJUGATE VACCINE
  • STREPTOCOCCUS-PNEUMONIAE
  • UTILITY ANALYSIS
  • BIRTH COHORT
  • DISEASE
  • BURDEN
  • TAIWAN
  • CARRIAGE
  • INFANTS

Cite this